"Not So Different:" How Biosimilars Advanced in 2018
Last year was a banner year for biosimilars, both in the United States and abroad. In this episode of the podcast, Laura Joszt, associate editorial director of The American Journal of Managed Care®, the parent publication of The Center for Biosimilars®, interviews senior editor, Kelly Davio, about the key developments in biosimilars last year.
Last year was a banner year for biosimilars, both in the United States and abroad. In this episode of the podcast, Laura Joszt, associate editorial director of The American Journal of Managed Care®, the parent publication of The Center for Biosimilars®, interviews senior editor, Kelly Davio, about the key developments in biosimilars last year.
To read more about some of the biosimilars discussed in this episode, follow these links:
- Coherus to Match Mylan on Price for Its Pegfilgrastim Biosimilar
- After Biosimilar Deals, UK Spending on Adalimumab Will Drop by 75%
- Pfizer Launches Epoetin Alfa Biosimilar, Retacrit, at 33.5% Discount to Reference Epogen
